X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.393 0.0036 (0.92%) Market Cap: 67.03 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 30/100

X4 Pharmaceuticals Inc Post-EHA Corporate Update Transcript

Jun 12, 2020 / 12:30PM GMT
Release Date Price: $8.52 (+6.77%)
Operator

Greetings and welcome to X4 Pharmaceuticals Post-EHA Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host, Candice Ellis, Director of Corporate Communications and Investor Relations at X4. You may begin.

Candice Ellis
X4 Pharmaceuticals - Director, Corporate Communications & IR

Thank you, Andrew, and good morning everyone. Thanks so much for joining us as we discuss the positive clinical data on our lead candidate, mavorixafor, in patients with WHIM syndrome which was presented virtually earlier this morning at the 25th European Hematology Association or EHA Annual Congress.

As a reminder, we'll be making forward-looking statements regarding our regulatory and product development plan as well as our research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 10-K on file with the SEC.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot